| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2016-02-04 | Immunogen (USA - MA) Merck&co (USA | IMGN853 - mirvetuximab soravtansine and Keytruda® (pembrolizumab) | ovarian cancer | clinical research |
Cancer - Oncology | Clinical research agreement |
| 2016-02-04 | Selvita (Poland) | opening of new premises |
Opening of new premises | |||
| 2016-02-04 | Eisai (Japan) Esteve (Spain) | Fycompa® (perampanel) | adjunctive treatment of primary generalised tonic-clonic (PGTC) seizures in adults and adolescents (?12 years) with idiopathic generalised epilepsy (IGE) | distribution |
Rare diseases - CNS diseases - Neurological diseases | Distribution agreement |
| 2016-02-04 | OncoGenex Pharmaceuticals (USA - WA) | restructuring |
Restructuring | |||
| 2016-02-03 | The Medicines Company (USA - NJ) | nomination |
Nomination | |||
| 2016-02-03 | Maxivax (Switzerland) | nomination |
Cancer - Oncology | Nomination | ||
| 2016-02-03 | Mersana Therapeutics (USA - MA) Takeda Pharmaceutical (Japan) | Fleximer® antibody drug conjugate (ADC) platform, XMT-1522 | collaboration R&D licensing |
Cancer - Oncology | Collaboration agreement | |
| 2016-02-03 | Quantum Genomics (France) | nomination |
Cardiovascular diseases | Nomination | ||
| 2016-02-03 | Quantum Genomics (France) | opening of new premises |
Cardiovascular diseases | Opening of new premises | ||
| 2016-02-03 | Maxivax (Switzerland) | chief executive officer | nomination | Cancer - Oncology | Nomination | |
| 2016-02-02 | PharmaMar (Spain) Specialised Therapeutics Asia Pte (Singapore) | Aplidin® (plitidepsin) | hematological cancers | licensing commercialisation |
Cancer - Oncology | Licensing agreement |
| 2016-02-02 | Anagenesis Biotechnologies (France) Ksilink (Germany) | small molecule therapies | Duchenne muscular dystrophy | R&D |
Neuromuscular diseases - Regenerative medicine | R&D agreement |
| 2016-02-02 | Oasmia Pharmaceutical (Sweden) | nomination |
Cancer - Oncology - Veterinary medicine | Nomination | ||
| 2016-02-02 | Teva Pharmaceutical Industries (Israel) AbCellera (Canada) | rare monoclonal antibodies | collaboration R&D |
Technology - Services | Collaboration agreement | |
| 2016-02-01 | Poxel (France) | nomination |
Metabolic diseases | Nomination | ||
| 2016-02-01 | The Medicines Company (USA - NJ) Mallinckrodt (Ireland) | Recothrom® Thrombin topical (Recombinant), PreveLeak™ (surgical sealant), Raplixa™ (fibrin sealant) | pipeline acquisition product acquisition |
Pipeline acquisition | ||
| 2016-02-01 | Aduro Biotech (USA - CA) Janssen Biotech, a J&J company (USA - NJ) | LADD immunotherapy platform including ADU-741, GVAX technology | prostate cancer | licensing |
Cancer - Oncology | Milestone |
| 2016-02-01 | Aduro Biotech (USA - CA) Janssen Biotech, a J&J company (USA - NJ) | ADU-214 and other product candidates engineered | lung cancer | licensing |
Cancer - Oncology | Milestone |
| 2016-02-01 | Array BioPharma (USA - CO) Dana-Farber Cancer Institute (USA - MA) | novel immune-oncology targets | R&D |
Cancer - Oncology | R&D agreement | |
| 2016-02-01 | Cempra (USA - NC) Macrolide Pharmaceuticals (USA - MA) | solithromycin | manufacturing - production | Production agreement |
